

CITATION REPORT

List of articles citing

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial.

DOI: 10.3389/fonc.2021.766500
Frontiers in Oncology, 2021, 11, 766500.

Source: <https://exaly.com/paper-pdf/135567350/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Prognostic and predictive molecular biomarkers in advanced colorectal cancer. 2022 , 236, 108239		1
5	Short bevacizumab infusion as an effective and safe treatment for colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022 , 17,	1.6	0
4	Emerging evidence of immunotherapy for colorectal cancer.		0
3	Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients. 2023 , 24, 1		0
2	Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer. 2023 , 34, 451-454		1
1	Targeting angiogenesis in oncology, ophthalmology and beyond.		0